Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nearing Finish Line, HCV Race Focuses On Salvage Therapy

Executive Summary

With few remaining unmet needs in hepatitis C, Gilead, Merck and AbbVie are focusing on tough-to-treat niches with their next-gen combination regimens, especially treatment-experienced patients who failed on prior direct-acting antiviral therapy. Merck also is studying injectable drug users in an effort to eradicate HCV entirely.

Advertisement

Related Content

Gilead Completes HCV Clinical Development With Vosevi Approval
AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients
Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
Combination Strategies A Common Thread In NASH R&D
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
Tackling Tough-To-Treat Patients As HCV Cure Rates Near 100%
Merck Hep C Drug Zepatier OK'd

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel